YIH
TCRX icon

Y-Intercept (HK)’s TScan Therapeutics TCRX Stock Holding History

Y-Intercept (HK)’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-76,660
Closed -$111K – 2039
2025
Q2 		$111K Buy
+76,660
New +$111K ﹤0.01% 1526
2024
Q2 		– Sell
-24,446
Closed -$194K – 1913
2024
Q1 		$194K Buy
24,446
+9,441
+63% +$59.4K 0.01% 1165
2023
Q4 		$87.5K Buy
+15,005
New +$68.7K 0.01% 1111

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Y-Intercept (HK)'s TCRX Position: Q3 2025 in Review

Y-Intercept (HK) sold out of TScan Therapeutics (TCRX) in Q3 2025, closing a stake of 76,660 shares — an estimated $111K sold.

Y-Intercept (HK) first reported a position in TCRX in Q4 2023 and held it in 3 quarters. The position peaked at $194K in Q1 2024. 73 funds tracked by Wall St. Rank hold TCRX as of Q3 2025.

  • Y-Intercept (HK) reported no remaining TScan Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 76,660 TScan Therapeutics shares in Q3 2025, an estimated $111K.
  • Y-Intercept (HK) first reported a position in TScan Therapeutics in Q4 2023 and held it in 3 quarters.
  • Y-Intercept (HK)'s TScan Therapeutics position peaked at $194K in Q1 2024.
  • 73 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.